DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2

Yanmin Zhang, Shuoxing Jiang, Dongdong Zhang, Xiaoguang Bai, Sidney Hecht, Shengxi Chen

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


In this study, we have prepared a DNA-affibody nanoparticle which mimics a antibody in its ability to specifically target the HER2 receptor. This nanoparticle has a smaller size (95 kDa) than the monoclonal antibody, trastuzumab (150 kDa) and at least two-fold greater activity toward BT474 cells than trastuzumab. The DNA in this nanoparticle structure has two functions, namely as a support to anchor two affibody molecules and as a vehicle to non-covalently bind multiple copies of a small molecule drug for drug delivery. Each DNA-affibody nanoparticle can bind ∼53 molecules of doxorubicin (DOX) to form a complex, which exhibits greater selectivity toward and inhibition of breast cancer cells overexpressing HER2 than doxorubicin does. As expected, the nanoparticle exhibits lesser inhibition of cells expressing HER2 at a low level. Thus, the nanoparticle represents a highly efficacious agent for inhibiting cancer cells which overexpress HER2, but with low toxicity toward normal cells.

Original languageEnglish (US)
Pages (from-to)573-576
Number of pages4
JournalChemical Communications
Issue number3
StatePublished - 2017

ASJC Scopus subject areas

  • Catalysis
  • Electronic, Optical and Magnetic Materials
  • Ceramics and Composites
  • Chemistry(all)
  • Surfaces, Coatings and Films
  • Metals and Alloys
  • Materials Chemistry


Dive into the research topics of 'DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2'. Together they form a unique fingerprint.

Cite this